Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX6O9V
|
|||
| Drug Name |
TC-210
|
|||
| Drug Type |
TCR-T cell therapy
|
|||
| Indication | Cholangiocarcinoma [ICD-11: 2C12.10; ICD-10: C22.1] | Phase 1/2 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25] | Phase 1/2 | [1] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [1] | ||
| Peritoneal mesothelioma [ICD-11: 2C51.2] | Phase 1/2 | [1] | ||
| Company |
TCR2 Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mesothelin (MSLN) | Target Info | . | [2] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of TCR2 Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.